Significance of an exon 2 G4C14-to-A4T14 polymorphism in the p73 gene on survival in rectal cancer patients with or without preoperative radiotherapy

Radiotherapy and Oncology

Volumn 92, Issue 2, 2009, Pages 215-220

  Lööf, Jasmine ^a   Pfeifer, Daniella ^a   Adell, Gunnar ^b   Sun, Xiao Feng ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

p73; Polymorphism; Preoperative radiotherapy; Rectal cancer; Survival

Indexed keywords

DNA; PROTEIN P53; PROTEIN P73; SURVIVIN;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DISEASE ASSOCIATION; DNA EXTRACTION; DNA POLYMORPHISM; EXON; FEMALE; FOLLOW UP; GENE EXPRESSION; GENOTYPE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECTUM CANCER; TREATMENT OUTCOME; TUMOR CLASSIFICATION; TUMOR DIFFERENTIATION;

ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; DNA-BINDING PROTEINS; EXONS; FEMALE; GENES, P53; GENOTYPE; HUMANS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NUCLEAR PROTEINS; POLYMORPHISM, GENETIC; RECTAL NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 67650992087     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2009.06.007     Document Type: Article

References (34)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. Improved Survival with Preoperative Radiotherapy in Resectable Rectal Cancer. Swedish rectal cancer trial. N Engl J Med 336 (1997) 980-987
3. Kaghad M., Bonnet H., Yang A., et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90 (1997) 809-819
4. Jost C.A., Marin M.C., and Kaelin Jr. W.G. p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature 389 (1997) 191-194
5. Yang A., Walker N., Bronson R., et al. P73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 404 (2000) 99-103
6. Stiewe T., and Putzer B.M. Role of p73 in malignancy: tumor suppressor or oncogene?. Cell Death Differ 9 (2002) 237-245
7. Guan M., Peng H.X., Yu B., and Lu Y. P73 overexpression and angiogenesis in human colorectal carcinoma. Jap J Clin Oncol 33 (2003) 215-220
8. Sun X.F. P73 overexpression is a prognostic factor in patients with colorectal adenocarcinoma. Clin Cancer Res 8 (2002) 165-170
9. Choi J.E., Kang H.G., Chae M.H., et al. No association between p73 G4C14-to-A4T14 polymorphism and the risk of lung cancer in a Korean population. Biochem Genet 44 (2006) 543-550
10. Ge H., Wang Y.M., Cao Y.Y., et al. The p73 polymorphisms are not associated with susceptibility to esophageal squamous cell carcinoma in a high incidence region of China. Dis Esophagus 20 (2007) 290-296
11. Hu Z., Miao X., Ma H., et al. Dinucleotide polymorphism of p73 gene is associated with a reduced risk of lung cancer in a Chinese population. Int J Cancer 114 (2005) 455-460
12. Li G., Sturgis E.M., Wang L.E., et al. Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of squamous cell carcinoma of the head and neck. Carcinogenesis 25 (2004) 1911-1916
13. Li H., Yao L., Ouyang T., et al. Association of p73 G4C14-to-A4T14 (GC/AT) polymorphism with breast cancer survival. Carcinogenesis 28 (2007) 372-377
14. Niwa Y., Hamajima N., Atsuta Y., et al. Genetic polymorphisms of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro and the risk of cervical cancer in Japanese. Cancer Lett 205 (2004) 55-60
15. Niwa Y., Hirose K., Matsuo K., et al. Association of p73 G4C14-to-A4T14 polymorphism at exon 2 and p53 Arg72Pro polymorphism with the risk of endometrial cancer in Japanese subjects. Cancer Lett 219 (2005) 183-190
16. Ryan B.M., McManus R., Daly J.S., et al. A common p73 polymorphism is associated with a reduced incidence of oesophageal carcinoma. Br J Cancer 85 (2001) 1499-1503
17. Li G., Wang L.E., Chamberlain R.M., Amos C.I., Spitz M.R., and Wei Q. P73 G4C14-to-A4T14 polymorphism and risk of lung cancer. Cancer Res 64 (2004) 6863-6866
18. Pfeifer D., Arbman G., and Sun X.F. Polymorphism of the p73 gene in relation to colorectal cancer risk and survival. Carcinogenesis 26 (2005) 103-107
19. Pfeifer D., Gao J., Adell G., and Sun X.F. Expression of the p73 protein in rectal cancers with or without preoperative radiotherapy. Int J Rad Oncol Biol Phys 65 (2006) 1143-1148
20. Adell G., Sun X.F., Stal O., Klintenberg C., Sjodahl R., and Nordenskjold B. P53 status: an indicator for the effect of preoperative radiotherapy of rectal cancer. Radiother Oncol 51 (1999) 169-174
21. Knutsen A., Adell G., and Sun X.F. Survivin expression is an independent prognostic factor in rectal cancer patients with and without preoperative radiotherapy. Int J Rad Oncol Biol Phys 60 (2004) 149-155
22. Benard J., Douc-Rasy S., and Ahomadegbe J.C. TP53 family members and human cancers. Hum Mutat 21 (2003) 182-191
23. Coates P.J. Regulating p73 isoforms in human tumours. J Pathol 210 (2006) 385-389
24. Melino G., De Laurenzi V., and Vousden K.H. P73: friend or foe in tumorigenesis. Nat Rev 2 (2002) 605-615
25. Grob T.J., Novak U., Maisse C., et al. Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ 8 (2001) 1213-1223
26. Stiewe T., Theseling C.C., and Putzer B.M. Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis. J Biol Chem 277 (2002) 14177-14185
27. Li F., Ambrosini G., Chu E.Y., et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396 (1998) 580-584
28. Shin S., Sung B.J., Cho Y.S., et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 40 (2001) 1117-1123
29. Kawasaki H., Toyoda M., Shinohara H., et al. Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer 91 (2001) 2026-2032
30. Rodel F., Hoffmann J., Distel L., et al. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 65 (2005) 4881-4887
31. Rodel C., Haas J., Groth A., Grabenbauer G.G., Sauer R., and Rodel F. Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor. Int J Rad Oncol Biol Phys 55 (2003) 1341-1347
32. Sah N.K., Khan Z., Khan G.J., and Bisen P.S. Structural, functional and therapeutic biology of survivin. Cancer Lett 244 (2006) 164-171
33. Wang Z., Fukuda S., and Pelus L.M. Survivin regulates the p53 tumor suppressor gene family. Oncogene 23 (2004) 8146-8153
34. Hoffman W.H., Biade S., Zilfou J.T., Chen J., and Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 277 (2002) 3247-3257